Menu

1 / 30

The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters

The Hill News·Eric Wargotz, opinion contributor·about 12 hours ago
#hlXrosZN
#thehill#hill#opinions#healthcare#opinion
Long article (768 words) — no AI summary yet.
Reading 0:00
15s threshold

The views expressed by contributors are their own and not the view of The Hill

The GLP-1 blind spot: Why the FDA’s new eye stroke warning matters

by Eric Wargotz, opinion contributor - 11/19/26 12:30 PM ET

by Eric Wargotz, opinion contributor - 11/19/26 12:30 PM ET

FILE – Boxes for the medications Wegovy and Zepbound are arranged for a photograph in California, May 8, 2025. (AP Photo/JoNel Aleccia, File)

The Food and Drug Administration’s drug safety communication on GLP-1 drugs should serve as a wake-up call for patient safety and corporate accountability.

The federal agency is forcing drugmakers to update warnings for blockbusters like Ozempic and Zepbound. They must now clearly state the risk of a rare, permanent blinding condition called non-arteritic anterior ischemic optic neuropathy. This happens when sudden blocked blood flow to the optic nerve causes painless, irreversible vision loss.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.